MyFinsight
Home
Blog
About
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$18,075K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Accounts payable
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Accrued clinical trial expenses
Prepaid expenses and other curre...
Proceeds from private placement,...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-32,718
-20,737
-25,138
-26,451
Depreciation
11
12
12
15
Stock-based compensation expense
2,524
2,396
2,419
2,461
Amortization of premiums and accretion of discounts on marketable securities, net
186
-25
-110
275
Change in fair value of embedded derivatives
-160
460
-170
-440
Amortization of right-of-use asset
34
34
33
32
Realized gain on marketable securities
0
6
42
14
Noncash interest expense
362
346
346
329
Other noncash expense
-
-
0
0
Prepaid expenses and other current assets
620
-691
-157
509
Other long-term assets
4
0
2
-24
Accounts payable
11,778
1,047
-128
-1,421
Accrued clinical trial expenses
-1,920
-2,433
732
-1,224
Accrued expenses and other liabilities
2,504
-5,043
2,235
-3,896
Finance lease liability
-
-
0
0
Net cash used in operating activities
-18,075
-24,128
-19,096
-30,489
Purchases of marketable securities
0
40,823
0
0
Proceeds from maturities and sales of marketable securities
26,000
27,016
26,250
40,511
Purchases of property and equipment
0
0
0
0
Net cash provided by investing activities
26,000
-13,807
26,250
40,511
Proceeds from issuance of common stock, net of issuance costs
-
-
0
0
Proceeds from private placement, net of offering costs
-305
35,746
-
-
Proceeds from exercise of stock options
27
145
2
0
Payment for financing lease
-
-
0
0
Payments for deferred offering costs
-
-
0
0
Repurchase of common shares to pay employee withholding taxes
0
149
0
0
Net cash provided by (used in) financing activities
-278
35,742
2
0
Net change in cash and cash equivalents and restricted cash
7,647
-2,193
7,156
10,022
Cash and cash equivalents and restricted cash at the beginning of the period
52,027
54,220
47,064
35,859
Cash and cash equivalents and restricted cash at the end of the period
59,674
52,027
54,220
47,064
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
and sales of...
$26,000K
(-75.31%↓ Y/Y)
Net cash provided by
investing activities
$26,000K
(-61.29%↓ Y/Y)
Net change in cash
and cash...
$7,647K
(546.41%↑ Y/Y)
Canceled cashflow
$18,353K
Accounts payable
$11,778K
(432.24%↑ Y/Y)
Stock-based compensation
expense
$2,524K
(-49.24%↓ Y/Y)
Accrued expenses and
other liabilities
$2,504K
(-49.54%↓ Y/Y)
Noncash interest
expense
$362K
(-40.95%↓ Y/Y)
Change in fair value of
embedded derivatives
-$160K
(-206.67%↓ Y/Y)
Amortization of right-of-use
asset
$34K
(-44.26%↓ Y/Y)
Depreciation
$11K
(-64.52%↓ Y/Y)
Proceeds from exercise of
stock options
$27K
(-27.03%↓ Y/Y)
Net cash used in
operating activities
-$18,075K
(72.59%↑ Y/Y)
Net cash provided by
(used in) financing...
-$278K
(-672.22%↓ Y/Y)
Canceled cashflow
$17,373K
Canceled cashflow
$27K
Net loss
-$32,718K
(53.09%↑ Y/Y)
Proceeds from private
placement, net of offering...
-$305K
Accrued clinical trial
expenses
-$1,920K
(54.67%↑ Y/Y)
Prepaid expenses and
other current assets
$620K
(136.17%↑ Y/Y)
Amortization of premiums and
accretion of discounts on...
$186K
(-71.12%↓ Y/Y)
Other long-term
assets
$4K
(122.22%↑ Y/Y)
Buy us a coffee